Business · Companies · 7 hrs ago
Almirall sales rise 8.3% as nine-month profit grows 36.3%
Almirall's net sales rose 8.3% in the first nine months of the year, reaching €889 million.
The Catalan pharmaceutical company said dermatology brought in €520 million, with sales in the segment up more than 17.6% from a year earlier.
Its earnings before interest, taxes, depreciation and amortisation rose 22.7% to €222 million.
Net profit increased 36.3% to €53.3 million after tax.
The company said growth was supported by its dermatology business in Europe and positive progress for biological treatments for atopic dermatitis and psoriasis.
Almirall kept its full-year forecasts unchanged, expecting sales growth of 9% to 12% and earnings before interest, taxes, depreciation and amortisation of €270 million to €290 million.
These forecasts set out the company’s expectations for the rest of the financial year.
Almirall’s net sales rose 8.3% in the first nine months of the year to €889 million.
Net profit increased 36.3% to €53.3 million.
Dermatology sales reached €520 million, up more than 17.6% year on year.
Ebitda rose 22.7% to €222 million.
The company confirmed its full-year forecast for sales growth of 9% to 12% and ebitda of €270 million to €290 million.
- Who
- Almirall, a pharmaceutical company.
- What
- Net sales rose 8.3% and net profit grew 36.3% in the first nine months of the year.
- When
- The results cover the first nine months of the year and were reported on Monday.
- Where
- Not stated.
- Why
- Growth was driven by its dermatology business, including sustained growth in Europe.
This story does not have two clearly opposing sides.
Almirall recorded net sales of €889 million, ebitda of €222 million and net profit of €53.3 million.
The company reported its results and confirmed its full-year financial forecasts.
- Net sales
- €889 million, up 8.3%
- Net profit
- €53.3 million, up 36.3%
- Ebitda
- €222 million, up 22.7%
- Dermatology sales
- €520 million, up more than 17.6% year on year
- Full-year sales forecast
- Growth of 9% to 12%
- Full-year ebitda forecast
- €270 million to €290 million
What people are saying
Our strong third-quarter results are in line with our expectations and our long-term growth trajectory, driven by the sustained growth of our dermatology business in Europe and the positive performance of our biologic treatment for atopic dermatitis and our biologic therapeutic alternative for psoriasis.